No abstract

Short-term administration of metformin to overweight or obese women with PCOS undergoing IVF decreased number of the retrieved oocytes but did not improve the LBR. Synopsis Metformin use could decrease the number of retrieved oocytes in overweight and obese women with polycystic ovary syndrome undergoing IVF.

Doubling the prophylactic iron dose is comparable to single dose in the prevention of iron deficiency anemia among women with twin gestations with more side effects.

No abstract

To determine the effectiveness of personalized embryo transfer (pET) versus frozen embryo transfer (FET) or fresh embryo transfer (ET) in infertile patients undergoing IVF at their first appointment. In pET, embryo transfer is performed within the optimal window of implantation identified by the endometrial receptivity analysis (ERA).DESIGN: Multicenter randomized clinical trial. Participants aged % 37 years scheduled for IVF with elective blastocyst transfer at the first appointment were randomized to undergo pET, FET or ET.MATERIALS AND METHODS: Setting: 16 reproductive medicine centers in Europe, America and Asia with a common reference genetic laboratory.Patient(s): We recruited 569 women, and 458 were randomly assigned to pET (N¼148), FET (N¼154), or ET (N¼156) groups.Intervention(s): The ERA test was performed using hormone replacement therapy guiding embryo transfer in the pET arm. Blastocyst vitrification was performed in the pET and FET arms. Blastocyst transfer in all groups.Main outcome measure(s): The primary outcome was live birth. Secondary outcomes were pregnancy and implantation rates as well as clinical miscarriage, biochemical pregnancy, and obstetric and neonatal outcomes. We performed intention-to-treat and per protocol analyses.RESULTS: In the per protocol analysis, live birth rates at the first embryo transfer were 45 of 80 (56.2%) in the pET group, 39 of 92 ( 42.4%) in the FET group, and 43 of 94 (45.7%) in the ET group (pET versus FET relative risk [RR] 1.35, 95% confidence interval (CI) 0.97-1.86; p¼0.09; pET versus ET [RR] 1.26, 95% (CI) 0.91-1.74; p¼0.17). Cumulative live birth rates after 12 months were 57 of 80 (71.2%) in the pET group, 51 of 92 (55.4%) in the FET group, and 46 of 94 (48.9%) in the ET group (pET versus FET [RR] 1.47, 95% (CI)1.01-2.13; p¼0.04; PET versus ET [RR]1.71, 95% (CI) 1.17-2.49; p¼0.003).Pregnancy rates at the first embryo transfer in the pET, FET and ET were 72.5%, 54.3% and 58.5% respectively (RR 1.56 pET versus FET, 95% CI 1.07 to 2.29, p¼0.01; pET versus ET 1.42, 0.98-2.08, p¼0.05). Implantation rates at the first embryo transfer were 57.3%, 43.2% and 38.6%, respectively (pET versus FET RR 1.37, 95%CI 1.03-1.82, p¼0.03; pET versus ET RR 1.54, 95%CI 1.15-2.05, p¼0.004).No differences between groups were found for clinical miscarriage, biochemical pregnancy or any other secondary outcomes. Obstetrical outcomes, type of delivery and neonatal outcomes were similar in all groups.CONCLUSIONS: In this RCT, we found a statistically significant improvement in cumulative live birth rates in pET compared to FET and ET. Pregnancy and implantation rates after pET over FET and ET at first attempt as well as in cumulative rates were significantly higher. These findings indicate the potential of pET with the ERA test at the first appointment that should be confirmed in larger randomized clinical trials. (ClinicalTrials. gov NCT 01954758).